AAD 2024

A recent case series reports significant symptom improvement in periorbital atopic dermatitis symptoms with the use of tacrolimus ointment, with minimal side effects. This approach marks a notable advancement in dermatological and ophthalmological care, offering a promising alternative to traditional steroid treatments. Tacrolimus ointment shows promising outcomes in treating periorbital atopic dermatitis with minimal adverse...

Hyperspectral imaging emerges as a potential tool in diagnosing erythema severity within atopic dermatitis, offering improved accuracy over traditional visual assessments. This innovative approach could improve objectivity and efficiency in skin inflammation evaluation. Hyperspectral imaging offers a detailed evaluation of erythema, surpassing traditional visual assessments. This study compared the efficacy of hyperspectral imaging against conventional...

Significant health literacy limitations may exist among atopic dermatitis patients, highlighting the need for tailored healthcare communication and support. A cross-sectional study associates limited health literacy with poorer health-related quality of life and older age, suggesting potential ways to improve patient care. Nearly one-third of atopic dermatitis patients exhibit limited health literacy, impacting their ability...

A recent observational study reveals that measuring skin tape soluble protein concentrations can offer a more objective assessment of eczema severity, particularly addressing the underestimationof severity in Black children with atopic dermatitis. The assessment of erythema in atopic dermatitis is challenging, especially in Black patients, leading to underestimation of disease severity. Skin tape soluble protein...

Health-tracking apps are useful for shared decision-making, according to a recent study that showed that eczema patients were willing to use disease progress and treatment tracking apps, providing valuable information to clinicians. Using mobile apps can contribute to disease management and may particularly be useful for improving shared decision-making (SDM), which can improve patient outcomes...

A sub-analysis of a multicountry study reports that, in addition to physical symptoms like pain and itching, individuals with AD also suffer from a decreased quality of life, which is evident through disrupted sleep, decreased ability to work, financial burdens, heightened anxiety/depression, and limited capacity to perform everyday tasks. Atopic dermatitis (AD) is a persistent,...

Dupilumab effectively manages atopic dermatitis by reducing clinical scores and improving itchiness, sleep quality, disease control, and overall quality of life, according to the results of a single-center retrospective study. Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by severe itching and recurrent eczematous skin lesions. AD is associated with symptoms such as...

Children and adolescents with atopic dermatitis are more inclined to exhibit aggressive behavior, which not only presents physical difficulties but additionally has a negative effect on their psychological well-being, according to the findings of a new cross-sectional study. Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by recurrent eczematous lesions and itching. Although...

Eblasakimab is efficacious and well-tolerated for treating adults with moderate-to-severe atopic dermatitis, according to a recent cohort study. Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease. Despite advances in systemic therapies for moderate-to-severe AD, therapeutic options remain limited. Eblasakimab is a novel human monoclonal antibody that binds the interleukin (IL)-13 receptor α1...